Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Prescribing Patterns of Dupilumab for Atopic Dermatitis in Adults: A Retrospective, Observational Cohort Study
ABSTRACT
Background:
Atopic dermatitis (AD) is a common inflammatory disease caused by type 2 helper T-cell (Th2) mediated immune response to environmental antigens. Dupilumab, a fully human monoclonal antibody, improves AD via inhibition of interleukin (IL)-4 and IL-13.
Objective:
Our aim was to characterize prescribing patterns of dupilumab for AD in adults at a large health system.
Methods:
A retrospective, observational cohort study was conducted using electronic data from the University of Colorado Medical Campus and its affiliates. The outcome measured was the prevalence of dupilumab prescribed for adults with AD, between 3/28/2013-3/28/2021. We assessed whether the characteristics of patients who received dupilumab were different from those who did not.
Results:
We found a population AD prevalence of 5.6%. In our cohort, Black patients were more than twice as likely to have received dupilumab than were White patients. Patients with a diagnosis of atopic neurodermatitis were approximately twice as likely to have received dupilumab than those with other diagnostic variants of AD.
Conclusions:
Our results demonstrate that both patient racial characteristics and specific AD diagnoses were associated with variations in dupilumab prescription patterns. Clinical Trial: NA
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.